Neurim Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
27 Habarzel St, Tel Aviv, Tel Aviv, 6971...Phone Number
+972 37684911Website
www.neurim.comRevenue
$5.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Neurim Pharmaceuticals
Neurim Pharmaceuticals Ltd. (www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug CIRCADIN®, is approved for patients over the age of 55 who are suffering from insomnia, and is commercially available in 45 countries around the world including Europe, Asia-Pacific, Latin America, Africa and the Middle East. Neurim has a strong and innovative product pipeline targeting diseases such as insomnia, Alzheimer's disease, dementia, and pain.Explore more
Neurim Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neurim Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Neurim Pharmaceuticals recently announced quarterly report
Check if Neurim Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Neurim Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Neurim Pharmaceuticals
Product Launch: Get notified when Neurim Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Neurim Pharmaceuticals has new funding data
Check out if Neurim Pharmaceuticals is spiking on competitors!
Neurim Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Neurim Pharmaceuticals
Find more new buyers
Company Profile Activity
Activity Insights
Neurim Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neurim Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neurim Pharmaceuticals.
Neurim Pharmaceuticals Tech Stack
A closer look at the technologies used by Neurim Pharmaceuticals
Neurim Pharmaceuticals News & Media
Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada
Prevalence of Autism Spectrum Disorder (ASD) among children and youth aged 1 to 17 years, is about 2% (1 in 50) and is equivalent to about 150,000 cases in Canada in 2025 [1, 2]. Smith-Magenis syndrome (SMS) is a very rare (1:15,000 to 1:25,000 births) genetic neurodevelopmental disorder...Health Canada Approves Slenyto® - Extended-Release Melatonin Formulation - as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome
TORONTO, Sept. 10, 2025 /PRNewswire/ -- Neurim Pharmaceuticals is pleased to announce that Health Canada has granted marketing authorization* for Slenyto®, an Extended-release melatonin minitablet indicated for the treatment of insomnia in children and adolescents aged 2 to <18 years with...NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
TEL AVIV, Israel, March 26, 2025 /PRNewswire/ -- Neurim Pharmaceuticals ("Neurim") announces that the European Commission has approved the extension of the indication to include the treatment of insomnia in children with attention deficit hyperactivity disorder (ADHD). The European...NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)
TEL-AVIV, Israel, July 30, 2024 /PRNewswire/ -- Neurim Pharmaceuticals ("Neurim") announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending an extension to the existing indication to include the treatment of Insomnia in children with Neurogenetic disorders (NGDs). Slenyto® is a child appropriate prolonged release melatonin formulation that was approved in the EU in 2018 for the treatment of insomni
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neurim Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Neurim Pharmaceuticals Ltd. (www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug CIRCADIN®, is approved for patients over the age of 55 who are suffering from insomnia, and is commercially available in 45 countries around the world including Europe, Asia-Pacific, Latin America, Africa and the Middle Eas... Read More
